SAN DIEGO--(BUSINESS WIRE)--June 27, 2006--Ophthonix Inc., a vision care company marketing high definition vision technology, which enables patients to see at the peak of their optical capability, has received its 13th patent. This patent provides for the precise measurement of the aberrations of the eye that are unique to each patient. These aberrations cause a lack of crispness in sight, even among patients who see 20/20, as well as limiting vision in low-light conditions such as driving at night.
